{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T18:33:31Z","timestamp":1773858811177,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangzhou Basic and Applied Basic Research Foundation","award":["202201011030"],"award-info":[{"award-number":["202201011030"]}]},{"name":"Ganzhou Science and Technology Program","award":["2023NS227010"],"award-info":[{"award-number":["2023NS227010"]}]},{"name":"Foundation of Department of Finance of Guangdong Province","award":["KS0120220269"],"award-info":[{"award-number":["KS0120220269"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"DOI":"10.1186\/s40170-026-00419-4","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:35:28Z","timestamp":1770896128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting FANCD2 to overcome enzalutamide resistance in prostate cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Wenzhen","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junquan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"3","key":"419_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"1","key":"419_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38\u201352.","journal-title":"Eur Urol"},{"issue":"10305","key":"419_CR3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet (London England). 2021;398(10305):1075\u201390.","journal-title":"Lancet (London England)"},{"issue":"5","key":"419_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/cncr.32630","volume":"126","author":"B Bernard","year":"2020","unstructured":"Bernard B, Burnett C, Sweeney CJ, Rider JR, Sridhar SS. Impact of age at diagnosis of de Novo metastatic prostate cancer on survival. Cancer. 2020;126(5):986\u201393.","journal-title":"Cancer"},{"issue":"16","key":"419_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453\u201365.","journal-title":"N Engl J Med"},{"issue":"11","key":"419_CR6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028\u201338.","journal-title":"N Engl J Med"},{"issue":"2","key":"419_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bph.15300","volume":"178","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, et al. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021;178(2):239\u201361.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"419_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.eururo.2014.09.049","volume":"67","author":"T Karantanos","year":"2015","unstructured":"Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67(3):470\u20139.","journal-title":"Eur Urol"},{"issue":"13","key":"419_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41388-024-03252-5","volume":"44","author":"S Dutta","year":"2025","unstructured":"Dutta S, Khedmatgozar H, Patel GK, Latour D, Welsh J, Mustafi M, et al. A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer. Oncogene. 2025;44(13):877\u201392.","journal-title":"Oncogene"},{"issue":"8027","key":"419_CR10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/s41586-024-07770-w","volume":"632","author":"P Alc\u00f3n","year":"2024","unstructured":"Alc\u00f3n P, Kaczmarczyk AP, Ray KK, Liolios T, Guilbaud G, Sijacki T, et al. FANCD2-FANCI surveys DNA and recognizes double- to single-stranded junctions. Nature. 2024;632(8027):1165\u201373.","journal-title":"Nature"},{"issue":"1","key":"419_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13000-019-0916-z","volume":"15","author":"H Hongo","year":"2020","unstructured":"Hongo H, Kosaka T, Aimono E, Nishihara H, Oya M. Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report. Diagn Pathol. 2020;15(1):5.","journal-title":"Diagn Pathol"},{"key":"419_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.freeradbiomed.2024.05.030","volume":"221","author":"M Shiota","year":"2024","unstructured":"Shiota M, Ushijima M, Tsukahara S, Nagakawa S, Okada T, Tanegashima T, et al. Oxidative stress in peroxisomes induced by androgen receptor Inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer. Free Radic Biol Med. 2024;221:81\u20138.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"419_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25(6):424\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"419_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47.","journal-title":"Mol Cancer"},{"issue":"6","key":"419_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35(6):830\u201349.","journal-title":"Cancer Cell"},{"issue":"7679","key":"419_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 Inhibition. Nature. 2017;551(7679):247\u201350.","journal-title":"Nature"},{"issue":"1","key":"419_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41467-018-02915-8","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Gao Z, Liu X, Agarwal P, Zhao S, Conroy DW, et al. Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance. Nat Commun. 2018;9(1):562.","journal-title":"Nat Commun"},{"issue":"5","key":"419_CR18","doi-asserted-by":"publisher","first-page":"eade9585","DOI":"10.1126\/sciadv.ade9585","volume":"9","author":"A Anandhan","year":"2023","unstructured":"Anandhan A, Dodson M, Shakya A, Chen J, Liu P, Wei Y, et al. NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8. Sci Adv. 2023;9(5):eade9585.","journal-title":"Sci Adv"},{"key":"419_CR19","doi-asserted-by":"publisher","first-page":"102726","DOI":"10.1016\/j.redox.2023.102726","volume":"63","author":"S Adinolfi","year":"2023","unstructured":"Adinolfi S, Patinen T, Jawahar Deen A, Pitkanen S, Harkonen J, Kansanen E, et al. The KEAP1-NRF2 pathway: targets for therapy and role in cancer. Redox Biol. 2023;63:102726.","journal-title":"Redox Biol"},{"key":"419_CR20","doi-asserted-by":"publisher","first-page":"155282","DOI":"10.1016\/j.phymed.2023.155282","volume":"124","author":"X Deng","year":"2024","unstructured":"Deng X, Lin B, Wang F, Xu P, Wang N. Mangiferin attenuates osteoporosis by inhibiting osteoblastic ferroptosis through Keap1\/Nrf2\/SLC7A11\/GPX4 pathway. Phytomedicine. 2024;124:155282.","journal-title":"Phytomedicine"},{"key":"419_CR21","doi-asserted-by":"publisher","first-page":"100985","DOI":"10.1016\/j.drup.2023.100985","volume":"70","author":"J Wang","year":"2023","unstructured":"Wang J, Zeng L, Wu N, Liang Y, Jin J, Fan M, et al. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2023;70:100985.","journal-title":"Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother"},{"key":"419_CR22","doi-asserted-by":"publisher","first-page":"101107","DOI":"10.1016\/j.redox.2019.101107","volume":"23","author":"M Dodson","year":"2019","unstructured":"Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019;23:101107.","journal-title":"Redox Biol"},{"issue":"4","key":"419_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"18","key":"419_CR24","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s40265-018-1029-9","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ, Enzalutamide. A review in Castration-Resistant prostate cancer. Drugs. 2018;78(18):1913\u201324.","journal-title":"Drugs"},{"issue":"1","key":"419_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12905-023-02857-4","volume":"24","author":"HH Lin","year":"2024","unstructured":"Lin HH, Zeng WH, Yang HK, Huang LS, Pan R, Lei NX. Fanconi anemia complementation group D2 promotes sensitivity of endometrial cancer cells to chemotherapeutic agents by inhibiting the ferroptosis pathway. BMC Womens Health. 2024;24(1):41.","journal-title":"BMC Womens Health"},{"issue":"43","key":"419_CR26","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1038\/sj.onc.1209878","volume":"25","author":"CG Mathew","year":"2006","unstructured":"Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006;25(43):5875\u201384.","journal-title":"Oncogene"},{"key":"419_CR27","first-page":"1414","volume":"09","author":"L Zhang","year":"2023","unstructured":"Zhang L, Wang L, Wang S. The function mechanism of FANCD2 and its research progress in tumors. J Chin Physician. 2023;09:1414\u20138.","journal-title":"J Chin Physician"},{"issue":"2","key":"419_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jgr.2019.12.007","volume":"45","author":"S He","year":"2021","unstructured":"He S, Lyu F, Lou L, Liu L, Li S, Jakowitsch J, et al. Anti-tumor activities of Panax Quinquefolius saponins and potential biomarkers in prostate cancer. J Ginseng Res. 2021;45(2):273\u201386.","journal-title":"J Ginseng Res"},{"issue":"1","key":"419_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41420-023-01430-0","volume":"9","author":"J Liang","year":"2023","unstructured":"Liang J, Liao Y, Wang P, Yang K, Wang Y, Wang K, et al. Ferroptosis landscape in prostate cancer from molecular and metabolic perspective. Cell Death Discovery. 2023;9(1):128.","journal-title":"Cell Death Discovery"},{"issue":"6","key":"419_CR30","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81(6):1583\u201394.","journal-title":"Cancer Res"},{"issue":"14","key":"419_CR31","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/0008-5472.CAN-23-1489","volume":"84","author":"RK Shrestha","year":"2024","unstructured":"Shrestha RK, Nassar ZD, Hanson AR, Iggo R, Townley SL, Dehairs J, et al. ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Cancer Res. 2024;84(14):2313\u201332.","journal-title":"Cancer Res"},{"issue":"4","key":"419_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/path.6245","volume":"262","author":"H Zhou","year":"2024","unstructured":"Zhou H, Wang YX, Wu M, Lan X, Xiang D, Cai R, et al. FANCD2 deficiency sensitizes SHH Medulloblastoma to radiotherapy via ferroptosis. J Pathol. 2024;262(4):427\u201340.","journal-title":"J Pathol"},{"key":"419_CR33","doi-asserted-by":"publisher","first-page":"921963","DOI":"10.3389\/fphar.2022.921963","volume":"13","author":"L Song","year":"2022","unstructured":"Song L, Wu J, Fu H, Wu C, Tong X, Zhang M. Abnormally expressed Ferroptosis-Associated FANCD2 in mediating the Temozolomide resistance and immune response in glioblastoma. Front Pharmacol. 2022;13:921963.","journal-title":"Front Pharmacol"},{"issue":"7","key":"419_CR34","doi-asserted-by":"publisher","first-page":"166788","DOI":"10.1016\/j.bbadis.2023.166788","volume":"1869","author":"J Lee","year":"2023","unstructured":"Lee J, Roh JL. Targeting Nrf2 for ferroptosis-based therapy: implications for overcoming ferroptosis evasion and therapy resistance in cancer. Biochim Biophys Acta Mol Basis Dis. 2023;1869(7):166788.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"419_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s11658-022-00383-z","volume":"27","author":"Y Li","year":"2022","unstructured":"Li Y, Xu B, Ren X, Wang L, Xu Y, Zhao Y, et al. Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62-Keap1-NRF2 pathway. Cell Mol Biol Lett. 2022;27(1):81.","journal-title":"Cell Mol Biol Lett"},{"key":"419_CR36","doi-asserted-by":"publisher","first-page":"102122","DOI":"10.1016\/j.redox.2021.102122","volume":"46","author":"X Ren","year":"2021","unstructured":"Ren X, Li Y, Zhou Y, Hu W, Yang C, Jing Q, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram\/copper-induced ferroptosis. Redox Biol. 2021;46:102122.","journal-title":"Redox Biol"},{"key":"419_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40170-020-00217-6","volume":"8","author":"KD Tousignant","year":"2020","unstructured":"Tousignant KD, Rockstroh A, Poad BLJ, Talebi A, Young RSE, Taherian Fard A, et al. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer Metabolism. 2020;8:11.","journal-title":"Cancer Metabolism"},{"key":"419_CR38","doi-asserted-by":"publisher","first-page":"118942","DOI":"10.1016\/j.lfs.2020.118942","volume":"267","author":"L Xie","year":"2021","unstructured":"Xie L, Wang Y, Chen Z. LncRNA Blnc1 mediates the permeability and inflammatory response of cerebral hemorrhage by regulating the PPAR-gamma\/SIRT6\/FoxO3 pathway. Life Sci. 2021;267:118942.","journal-title":"Life Sci"},{"key":"419_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.redox.2016.12.010","volume":"11","author":"JL Roh","year":"2017","unstructured":"Roh JL, Kim EH, Jang H, Shin D. Nrf2 Inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017;11:254\u201362.","journal-title":"Redox Biol"},{"issue":"2","key":"419_CR40","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4143\/crt.2016.572","volume":"50","author":"J Guo","year":"2018","unstructured":"Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, et al. Ferroptosis: A novel Anti-tumor action for cisplatin. Cancer Res Treat. 2018;50(2):445\u201360.","journal-title":"Cancer Res Treat"}],"container-title":["Cancer & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-026-00419-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-026-00419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-026-00419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:38:41Z","timestamp":1773833921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40170-026-00419-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1186\/s40170-026-00419-4","relation":{},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were carried out at Guangdong Provincial People\u2019s Hospital, and conducted in accordance with the national guidelines for the care and use of laboratory animals with approval from Guangdong Provincial People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}